The African psychoactive alkaloid Ibogaine, Schedule 1 in the USA, researched for substance use since the 1950’s, has demonstrated effectiveness in reversing tolerance & craving for opioids, stimulants & alcohol. Risks & fatalities are involved, due to the demographic, screening, inducing bradycardia, prolonging the QT interval & blocking the Potassium hERG channel, further complicated by opioid maintenance medications & psychiatric drugs. Almost all ibogaine centres, rapidly increasing in ...
Dana Beal – Nerve Growth Factor GDNF Elucidates Ibogaine’s Persistence & Immune Modulatory Effects
Ibogaine shares receptor effects with both Salvia divinorum (κ-opiate down-regulation of tolerance via beta-arrestin) and with ketamine (NMDA antagonism, curbing narcotic withdrawal and super-sensitization to stimulants). Additionally, ibogaine induces the nerve growth factor GDNF (Glia-Derived Neurotrophic Factor), re-sprouting chronically desensitised dopamine receptors and replacing the neural deficit experienced as craving. Moreover, the 10-fold GDNF spike engendered by ibogaine back-signals to cell nuclei to make more GDNF, setting up ...
Gabor Maté Talks Ibogaine for Addiction Interruption
Gabor Maté speaking at the Psychedelic Psychotherapy Forum in Victoria, BC in October 2015 with ibogaine provider Trevor Millar, owner of Liberty Root Therapy Ltd. www.libertyroot.net
source
The Action of Ibogaine
Ibogaine is the progressive process to help detox from drugs and stay off. Here we discuss the basics behind ibogaine’s mechanism of action and how it effects the brain during opiate detox. It is important to note that while Ibogaine is known as a tried and true detox for opiate users, it is also very effective for most other substance dependencies, problematic behaviors, and thought patterns. ...
Results of the Long-Term Outcomes Study of Ibogaine Treatment in Mexico – Thomas Kingsley Brown
http://psychedelicscience.org
Help us caption and translate this video on Amara.org: http://www.amara.org/en/videos/ypBoaytF37qb/info/
Results of the Long-Term Outcomes Study of Ibogaine Treatment in Mexico
Thomas Kingsley Brown, PhD
This presentation is an overview of the MAPS-funded study of long-term outcomes for ibogaine-assisted treatment of opiate dependence for patients at two clinics in Baja California, Mexico. Beginning in September of 2010, the study enrolled thirty US residents seeking ibogaine treatment for opiate dependence at the ...
Continue Reading →